NanoPass Technologies Ltd
NanoPass Technologies to Supply MicronJet600™ Device to Immune Design for Use in ZVex-based Oncology Immunotherapy Products NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600™, its microneedle delivery device, for use with Immune Design’s oncology immunotherapy products from its ZVex discovery platform. The agreement will provide Immune Design non-exclusive access and supply for use of the device in all of its relevant cancer immunotherapy programs globally. Financial terms
Gamida Cell plans to commence Phase III study of NiCord in 2016Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the company has reached agreements with the FDA and EMA regarding the Phase III study design outline of NiCord. The company is moving forward now with plans to commence an international, multi-center, Phase III study of NiCord in 2016. Phase I/II data of 15 patients are expected in Q4/2015. NiCord is in development as an experimental treatment for
ReWalk Robotics Ltd.
ReWalk Robotics Launches ReWalk 6.0: the Company’s Sixth Generation Personal System for Home & Community UseThis Version of the ReWalk Personal Exoskeleton Offers Users the Fastest Walking Speed, Most Natural Gait, and the Most Precise Fit of Any ExoskeletonYOKNEAM ILIT, ISRAEL / MARLBOROUGH, MASSACHUSETTS, July 14, 2015 — ReWalk Robotics Ltd. (Nasdaq: RWLK), the leading global exoskeleton manufacturer, unveiled today the latest edition of its Personal powered exoskeleton system—the ReWalk Personal 6.0—marking the company’s sixth generation community use product. The ReWalk Personal 6.0 offers those in the spinal cord injured